Rotigotine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Advanced Idiopathic Parkinson's Disease
Conditions
Advanced Idiopathic Parkinson's Disease
Trial Timeline
Sep 1, 2012 → Mar 1, 2013
NCT ID
NCT01711866About Rotigotine
Rotigotine is a approved stage product being developed by UCB for Advanced Idiopathic Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01711866. Target conditions include Advanced Idiopathic Parkinson's Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03103919 | Approved | Completed |
| NCT01976871 | Approved | Completed |
| NCT01782222 | Approved | Completed |
| NCT01723904 | Phase 3 | Completed |
| NCT01711866 | Approved | Completed |
| NCT01569464 | Phase 3 | Completed |
| NCT01498120 | Phase 2 | Completed |
| NCT01495793 | Phase 2 | Completed |
| NCT01300819 | Approved | Completed |
| NCT00594464 | Approved | Completed |
| NCT00593606 | Phase 3 | Completed |
| NCT00519532 | Phase 3 | Terminated |
| NCT00474058 | Phase 3 | Completed |
| NCT01964573 | Phase 1 | Completed |
| NCT00498108 | Phase 3 | Completed |
| NCT00263068 | Phase 3 | Completed |
| NCT00275236 | Phase 3 | Completed |
| NCT00135993 | Phase 3 | Completed |
| NCT00136045 | Phase 3 | Completed |
| NCT00505687 | Phase 3 | Completed |
Competing Products
20 competing products in Advanced Idiopathic Parkinson's Disease